NCT07215754
Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
Recruiting · Not specified · University of Pisa · registry updated 2025-10-10
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
BACKGROUND AND RATIONALE. The role of type I interferons (IFN) in innate and adaptive immunity has been extensively studied, establishing a key role for type I IFNs in immune homeostasis. With growing evidence that type I IFNs play an important role in autoimmune diseases, inhibition of type I IFN biological activity with Anifrolumab represents a significant therapeutic option in SLE. Phase II and III clinical trials have demonstrated the efficacy and safety of the drug in patients with moderate-to-severe active disease. OBJECTIVES. The primary objective of the study is to evaluate the clinical efficacy and incidence of adverse events associated with Anifrolumab therapy in a multicenter cohort of patients with SLE....
Inclusion
- Patients diagnosed with SLE according to classification criteria valid at diagnosis time (1997, 2012, 2019)
- Written informed consent
- Active disease for which the patient is a candidate for Anifrolumab treatment (including compassionate use)
- Active disease for which the patient has started Anifrolumab treatment
Exclusion
- Age \<18 years
- Absence of patient consent